Arcoxia pills 90mg №7

Packaging

7 pieces

Mechanism of action

ARKOKSIA - NPVS. Selective inhibitor of COX-2, in therapeutic concentrations, blocks the formation of prostaglandins and has anti-inflammatory, analgesic and antipyretic effects. Selective inhibition of COX-2 is accompanied by a decrease in the severity of clinical symptoms associated with the inflammatory process, and there is no effect on the function of platelets and the mucous membrane of the gastrointestinal tract.

Etoricoxib has a dose-dependent effect of inhibiting COX-2, without affecting COX-1 when used in a daily dose of up to 150 mg.Arcoxia^® no effect on the production of prostaglandins in the gastric mucosa and the time of bleeding. In the conducted studies, no decrease in arachidonic acid and platelet aggregation caused by collagen was observed.

Indications and usage

Symptomatic therapy of the following diseases and conditions:

- osteoarthritis;

- rheumatoid arthritis;

- ankylosing spondylitis;

- pain and inflammatory symptoms associated with acute gouty arthritis.

Contraindications

- A complete or incomplete combination of asthma, recurrent nasal polyposis or paranasal sinuses and intolerance to Acetylsalicylic acid and other NSAIDs (including a history of);

- erosive and ulcerative changes of the mucous membrane of the stomach or duodenum, active Gastrointestinal bleeding, cerebrovascular or other bleeding;

- inflammatory bowel disease (Crohn's disease, ulcerative colitis) in the acute phase;

- hemophilia and other bleeding disorders;

- severe heart failure (NYHA classification II-IV functional classes);

- severe liver failure (more than 9 points on the Child-Pugh scale) or active liver disease;

- renal failure severe (CC less than 30 ml / min), progressive kidney disease, confirmed hyperkalemia;

- the period after coronary artery bypass surgery; peripheral artery disease, cerebrovascular disease, clinically severe coronary artery disease;

- persistently maintained blood pressure values ​​greater than 140/90 mm Hg. st. with uncontrolled arterial hypertension;

- pregnancy

- lactation period (breastfeeding);

- children's age up to 16 years;

- Hypersensitivity to any component of the drug.

with caution use the drug in the presence of anamnestic data on the development of ulcerative lesions of the gastrointestinal tract, Helicobacter pylori infection, in the elderly, in patientsprolonged use of NSAIDs, often alcohol, with severe somatic diseases, dyslipidemia / hyperlipidemia, diabetes, hypertension, edema and fluid retention, smoking, in patients with QA less than 60 ml / min, with concomitant therapy with the following drugs: anticoagulants ( for example, warfarin), antiplatelet agents (for example, acetylsalicylic acid, clopidogrel), GCS (for example, prednisolone), selective serotonin reuptake inhibitors (for example, citalopram, fluox etine, paroxetine, sertraline).

Pregnancy and Breastfeeding

The drug is contraindicated in pregnancy and lactation.

The use of the drug may adversely affect female fertility and is not recommended for women planning a pregnancy.

Dosage and administration

The drug is taken orally, regardless of the meal, with a small amount of water.

Atosteoarthrosis The recommended dose is 60 mg 1 time / day.

Atrheumatoid arthritis and ankylosing spondylitis The recommended dose is 90 mg 1 time / day.

Atacute gouty arthritis recommended in the acute period, the dose is 120 mg 1 time / day.

The duration of use of the drug in a dose of 120 mg is not more than 8 days. The minimum effective dose should be used with the shortest possible short course.

The average therapeutic dose forpain syndrome makes once 60 mg.

Havepatients with hepatic insufficiency (5-9 points on the Child-Pugh scale) It is recommended not to exceed a daily dose of 60 mg.

Overdosage

Symptoms: With an overdose of the drug may cause undesirable effects on the gastrointestinal tract, cardiovascular system and kidneys.

Treatment: conduct symptomatic therapy. Etotrikoksib is not excreted by hemodialysis, the removal of the drug during peritoneal dialysis has not been studied.

At a temperature not higher than 30 ° C.

2 years